Institute of Child Health
- Athena SWAN
- Medical Illustration
- Laboratory Services
- Confocal Microscopy Core Facility
- Embryonic stem cell / Chimera production
- Flow Cytometry Core Facility
- Mass spectrometry
- UCL Genomics
- Events / Conferences
- Statistical Support Service
- Research and Innovation
- Strategic partners
- Contact us
- ICH Intranet
The Biological Mass Spectrometry Centre (BMSC) is a state of the art research centre which is housed in bespoke laboratories at the UCL Institute of Child Health and headed by Dr Kevin Mills. The Centre has both the capability to perform biomarker discovery type experiments and develop any of these diagnostic molecules into accredited, translational tests that can be used by the NHS and industry. If you would like more information regarding what instrumentation we have then please follow the link to the technology section. If you would like to use mass spectrometry in your research then please spend 5 minutes reading the Frequently Asked Questions before contacting us.
About the Biological Mass Spectrometry Centre
The Biological Mass Spectrometry Centre at the UCL Institute of Child Health is a specialised patient-focused, translational research centre and performs analyses using cutting edge mass spectral technology. The centre has over £6 million worth of mass spectrometry equipment including MALDI/tissue imaging, proteomics (2D DiGE and label free mass spectrometry), metabolomics, lipidomics, glycomics and targeted proteomics MRM based translational test development. The BMSC is staffed by over 20 full-time researchers and has over £6 million in grant funding. Our group works very closely with the BRC at Great Ormond Street Hospital and National Hospital for Neurology in both elucidating disease mechanisms involved in genetic metabolic disease and neurodegenerative conditions.
Our Translational Research
The BMSC is a unique, state of the art environment where both clinical
and non-clinical researchers work side by side using proteomics, metabolomics
and lipidomics to elucidate disease mechanisms in
rare and neurodegenerative diseases. The group also specialise in biomarker
discovery and translational test development for the NHS and industry, creating
new, more specific and accurate tests. These tests are of direct patient
benefit and allow us to diagnose diseases much more accurately and quicker than
ever before. In addition these bespoke assays are translated into the
accredited chemical pathology department at GOSH where they are used to diagnose
and monitor therapy or drug trials. Please click here for more information on our research interests.
The BMSC has a history of developing specialised clinical assays which we still provide as diagnostic services. We were the first centre to develop and offer the assay for urine Gb3 which is a marker used for diagnosis and monitoring of Fabry disease. This assay is now used around the world and we are a main centre for the assay for clinical trials.
We have also been providing a service for the analysis of urinary bile acids since 1984 that has helped diagnose many patients with inborn errors of metabolism.
- Available omic, mass spectral and diagnostic services
- Omics technologies used by the BMSC
- The BMSC Team, Research interests and opportunities
- Grants & Publications
BMSC logo kindly designed and provided by Adele Heywood